辉瑞制药终止反向合并条款表并评估战略替代方案

2025-03-01 05:26

Vincerx Pharma (NASDAQ:VINC) said on Friday that the previously signed binding term sheet between Vincerx, Oqory, and Vivasor, for a reverse merger transaction has been terminated.
As a result, the board of directors will reassess the company’s strategic alternatives, including out-licensing, merger and acquisition opportunities, the sale of assets and technologies, and winding down operations, among other potential transactions.
As of February 26, 2025, the company had approximately $3.9M in cash. The company’s cash runway is expected to extend through late Q2 2025.

More on Vincerx Pharma